Insmed Incorporated (NASDAQ:INSM) CEO Sells $188,686.08 in Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 2,978 shares of the firm's stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.36, for a total transaction of $188,686.08. Following the completion of the sale, the chief executive officer now owns 392,589 shares in the company, valued at $24,874,439.04. This represents a 0.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

William Lewis also recently made the following trade(s):

• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Stock Performance

Insmed stock traded down $0.47 during trading hours on Friday, reaching $65.25. 3,087,759 shares of the stock were exchanged, compared to its average volume of 1,881,810. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The stock has a market cap of $11.67 billion, a P/E ratio of -11.76 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm's 50 day moving average is $71.29 and its 200 day moving average is $72.44.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analysts' expectations of $93.36 million. During the same period in the prior year, the firm posted ($1.10) EPS. The firm's revenue for the quarter was up 18.1% compared to the same quarter last year. Analysts predict that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of recent research reports. Truist Financial reiterated a "buy" rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. boosted their price objective on Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a research note on Friday, November 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. Finally, Bank of America boosted their target price on shares of Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Insmed currently has an average rating of "Moderate Buy" and an average price target of $83.67.

Institutional Trading of Insmed

A number of institutional investors have recently modified their holdings of INSM. Orion Portfolio Solutions LLC boosted its position in shares of Insmed by 48.5% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company's stock worth $2,050,000 after purchasing an additional 9,170 shares in the last quarter. Ally Bridge Group NY LLC boosted its holdings in Insmed by 16.9% during the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company's stock worth $11,011,000 after buying an additional 21,833 shares in the last quarter. Vestal Point Capital LP grew its position in Insmed by 113.3% during the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock worth $116,800,000 after buying an additional 850,000 shares during the period. TimesSquare Capital Management LLC acquired a new stake in shares of Insmed during the 3rd quarter valued at approximately $35,322,000. Finally, Jennison Associates LLC boosted its stake in shares of Insmed by 3.4% during the 3rd quarter. Jennison Associates LLC now owns 769,253 shares of the biopharmaceutical company's stock worth $56,155,000 after acquiring an additional 24,973 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.